Want to see NXTC full AI Analyst Report?
NXTC Stock Chart & Stats
$4.24
$0.70(16.51%)
At close: 4:00 PM EDT
$4.24
$0.70(16.51%)
Day’s Range― - ―
52-Week Range$1.55 - $15.74
Previous CloseN/A
Volume127.65K
Average Volume (3M)37.58K
Market Cap
$30.44M
Enterprise Value-$7.31
Total Cash (Recent Filing)$20.09M
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Oct 29, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.58
Shares Outstanding4,577,359
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$20.00Price Target Upside371.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Merger And FundingThe transaction provides substantial capital and introduces Avere’s oral IL-23 program, potentially giving the combined company a funded path toward Phase 3 development and a more advanced commercial opportunity.
Clinical ValidationEarly clinical activity supports the potential value of the legacy oncology pipeline and may improve partnering or monetization prospects, although further trials are required to establish durability, safety, and registrational potential.
Low LeverageRelatively modest debt reduces fixed financial obligations and default risk compared with highly leveraged biotechnology peers, preserving some flexibility while the company advances clinical programs and undergoes its strategic transition.
Bears Say
No Commercial RevenueWithout product revenue, operations depend on financing, partnerships, or asset monetization. This leaves earnings power highly uncertain and makes the business especially sensitive to clinical outcomes and capital-market access.
Persistent Cash BurnSustained operating cash consumption means the company is not self-funding. Continued investment in development will likely require additional capital or strategic transactions, creating execution and funding risk over the next several quarters.
Dilution And Strategic DisruptionThe merger materially reduces legacy shareholder ownership and replaces the existing operating strategy and workforce. Integration, execution, and governance changes could disrupt development while legacy holders retain limited direct exposure.
NextCure News
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $1.55 and its highest was $15.74 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $30.44M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is Oct 29, 2026 which is in 69 days.
How were NextCure Inc’s earnings last quarter?
NextCure Inc released its earnings results on Aug 06, 2026. The company reported -$2.8 earnings per share for the quarter, missing the consensus estimate of -$1.95 by -$0.85.
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -0.9.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 4,577,359 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
NextCure Inc reported an EPS of -$2.8 in its last earnings report, missing expectations of -$1.95. Following the earnings report the stock price went up 4.472%.
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NextCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (371.70% Upside)
$20.00 (371.70% Upside)
Blogger Sentiment
Bullish
NXTC Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 27.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.57%
Trailing 12-Months
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
NXTC Stock 12 Month Forecast
Average Price Target
$20.00
▲(371.70% Upside)
Technical Analysis
GT Biopharma
―
Marker Therapeutics
―
Celularity
―
Werewolf Therapeutics
―
Senti Biosciences
―
Ownership Overview
22.53% Insiders
7.86% Mutual Funds
22.80% Other Institutional Investors
43.16% Public Companies and
Individual Investors